### BEST AVAILABLE COPY

#### PATENT COOPERATION TREATY

From the

NTERNATIONAL SEARCHING AUTH	ORITY		-	
To:			PCT	
see form PCT/ISA/220		WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY (PCT Rule 43 <i>bis.</i> 1)		
		Date of mailing (day/month/year) see	e form PCT/ISA/210 (second sheet)	
Applicant's or agent's file reference see form PCT/ISA/220		FOR FURTHER A See paragraph 2 belo		
International application No. PCT/IB2005/000597	International fiting date (d 07.03.2005	ay/month/year)	Priority date (day/month/year) 18.03.2004	
International Patent Classification (IPC) or C07D23140, C07D23142, C07D2	both national classification a 231,50, C07D401/12, C	and IPC 07D417/04, C07D4	103/12, C07D413/12, C07D417/12,	
Applicant PFIZER LIMITED				

1	. This opinion	contains i	ndications rela	iting to	the following	nems:

☐ Box No. VIII Certain observations on the international application

Box No. I	Basis of the opinion
Box No. II	Priority
Box No. III	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
☐ Box No. IV	Lack of unity of invention
☑ Box No. V	Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
Box No. VI	Certain documents cited
C Say No. VIII	Costella defects in the international application

#### **FURTHER ACTION**

If a demand for international preliminary examination is made, this opinion will usually be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA"). However, this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1 bis(b) that written opinions of this international Searching Authority will not be so considered.

If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of three months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.

For further options, see Form PCT/ISA/220.

For further details, see notes to Form PCT/ISA/220.

Name and mailing address of the ISA:



European Patent Office - P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk - Pays Bas Tel. +31 70 340 - 2040 Tx: 31 651 epo ni Fax: +31 70 340 - 3016

Allard, M

Authorized Officer

Telephone No. +31 70 340-2002



10/593133

## WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/IB2005/000597

1

_	Box	No. I Basis of the opinion
1.	With the la	regard to the <b>language</b> , this opinion has been established on the basis of the international application in inguage in which it was filed, unless otherwise indicated under this item.
	l:	This opinion has been established on the basis of a translation from the original language into the following anguage —, which is the language of a translation furnished for the purposes of international search under Rules 12.3 and 23.1(b)).
2.	With	regard to any nucleotide and/or amino acid sequence disclosed in the international application and assary to the claimed invention, this opinion has been established on the basis of:
	a. typ	e of material:
		a sequence listing
		table(s) related to the sequence listing
	b. for	mat of material:
	D	in written format
		in computer readable form
	c. tim	e of filing/furnishing:
		contained in the international application as filed.
		filed together with the international application in computer readable form.
	. 🗆	furnished subsequently to this Authority for the purposes of search.
3.	. (	n addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
4.	Addit	tional comments:
_	Вох	No. II Priority
1.	(	The validity of the priority claim has not been considered because the International Searching Authority does not have in its possession a copy of the earlier application whose priority has been claimed or, where required, a translation of that earlier application. This opinion has nevertheless been established on the assumption that the relevant date (Rules 43 <i>bis.</i> 1 and 64.1) is the claimed priority date.
2.		This opinion has been established as if no priority had been claimed due to the fact that the priority claim has been found invalid (Rules 43 bis.1 and 64.1). Thus for the purposes of this opinion, the international illing date indicated above is considered to be the relevant date.
3.	Addi	tional observations, if necessary:

## WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No.-PCT/IB2005/000597

	x No. III Non-establishment oblicability	o1 op	inion with regard to novelty, inventive step and industrial	
The	e questions whether the claimed rious), or to be industrially applic	inve able	ntion appears to be novel, to involve an inventive step (to be non have not been examined in respect of:	
	the entire international application,			
Ø	claims Nos. 15 (as to industrial applicability only)			
bed	because:			
	the said international application, or the said claims Nos. 15 relate to the following subject matter which does not require an international preliminary examination (specify):			
	see separate sheet			
	the description, claims or draw unclear that no meaningful opi	ings nion (	(indicate particular elements below) or said claims Nos. are so could be formed (specify):	
	the claims, or said claims Nos. could be formed.	are s	so inadequately supported by the description that no meaningful opinion	
	no international search report l	has b	een established for the whole application or for said claims Nos.	
	the nucleotide and/or amino ac C of the Administrative Instruct		quence listing does not comply with the standard provided for in Annex in that:	
	the written form		has not been furnished	
	•		does not comply with the standard	
	the computer readable form		has not been furnished	
			does not comply with the standard	
	the tables related to the nucleonot comply with the technical r	tide : equir	and/or amino acid sequence listing, if in computer readable form only, do ements provided for in Annex C-bis of the Administrative Instructions.	
	See separate sheet for further	detai	ils	

## WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/IB2005/000597

Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Yes: Claims

2, 4, 11

No: Claims

1, 3, 5-10, 12-15

Inventive step (IS)

Yes: Claims

: Claims

1-15

Industrial applicability (IA)

Yes: Claims

1-14

No: Claims

2. Citations and explanations

see separate sheet

#### Box No. VI Certain documents cited

 Certain published documents (Rules 43bis.1 and 70.10) and /or

2. Non-written disclosures (Rules 43bis.1 and 70.9)

see form 210

# 10/593133

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY (SEPARATE SHEET)

International application No.

PCT/IB2005/000597

#### Re Item III.

Claim 15 relates to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of this claim (Article 34(4)(a)(I) PCT).

#### Re Item V.

#### Reference is made to the following documents:

<u></u>	
D01:	EP 1 319 657 A (NIHON NOHYAKU CO., LTD.) 18 June 2003 (2003-06-18)
D02:	DE 195 11 269 A (CIBA-GEIGY AG) 5 October 1995 (1995-10-05)
D03:	DATABASE WPI, Section Ch, Week 199340, Derwent Publications Ltd.,
	London, GB; Class C02, AN 1993-317444, XP002330928 (JP 05 230029 A
	(UBE IND LTD) 7 September 1993 (1993-09-07))
D04:	DATABASE CAPLUS, CHEMICAL ABSTRACTS SERVICE, COLUMBUS,
	OHIO, US; XP002330924, Database accession no. 1965:431646
D05:	DATABASE CAPLUS, CHEMICAL ABSTRACTS SERVICE, COLUMBUS,
	OHIO, US; XP002330925, Database accession no. 1969:36415
D06:	DATABASE CAPLUS, CHEMICAL ABSTRACTS SERVICE, COLUMBUS,
	OHIO, US; XP002330926, Database accession no. 1964:3141
D07:	DATABASE CROSSFIRE, BEILSTEIN INSTITUT ZUR FOERDERUNG DER
	CHEMISCHEN WISSENSCHAFTEN; XP002330927
D08:	GUARNERI M ET AL: "Contributo alla conoscenza di pirazolsulfonamidi"
	ANNALI DI CHIMICA, vol. 49, 1959, pages 958-963, XP008048105
D09:	KOCH A ET AL: "QSAR and molecular modelling for a series of isomeric X-
	sulfanilamido-1-phenylpyrazoles" QUANTITATIVE STRUCTURE-ACTIVITY
	RELATIONSHIPS, vol. 12, no. 4, 1993, pages 373-382, XP008048108
D10:	ALBERTI C ET AL: "Sulfanilamidi pirazoliche. Nota VIII" FARMACO, EDIZIONE
	SCIENTIFICA, vol. 21, no. 12, 1966, pages 883-891, XP008048107
D11:	ALBERTI C ET AL: "Sulfanilamidi pirazoliche. Nota VI" FARMACO, EDIZIONE
	SCIENTIFICA, vol. 19, no. 7, 1964, pages 618-637, XP008048116
D12:	ALBERTI C ET AL: "Sulfanilamidi pirazoliche. Nota V" FARMACO, EDIZIONE

SCIENTIFICA, vol. 19, no. 5, 1964, pages 459-473, XP008048115

D13: ALBERTI C ET AL: "Sulfanilamidi pirazoliche. Nota IV" FARMACO, EDIZIONE SCIENTIFICA, vol. 17, no. 6, 1962, pages 460-467, XP008048106

D14: ALBERTI C ET AL: "Sulanilamidi pirazoliche. Nota XIII" FARMACO, EDIZIONE SCIENTIFICA, vol. 29, no. 12, 1974, pages 957-966, XP002330922

D15: ALBERTI C ET ET: "Sulfanilamidi pirazoliche. Nota XI" FARMACO, EDIZIONE SCIENTIFICA, vol. 26, no. 1, 1971, pages 66-88, XP002330923

D16: FUSCO R ET AL: "Sintesi e proprieta' farmacologiche di composti pirazolici.
Nota I" FARMACO, EDIZIONE SCIENTIFICA, vol. 23, no. 19, 1968, pages 919944, XP001085259

#### Novelty (Article 33(2) PCT)

The subject-matter of claims 1, 3, 5-10 and 12-15 lacks novelty in the light of the disclosure of

D4-D7,

D8 (see page 959),

D9 (see compounds of the 4-Series(IV)),

D10 (see page 885, compounds la-lc and II),

D11 (see page 620, compounds lia-Ilg),

D12 (see page 461, compound II with R = H),

D13 (see page 461, compounds II and III),

D14 (see page 959, compounds II, lia-IIc),

D15 (see page 68, compounds lia-lic) and

D16 (see page 921, table 1).

#### Inventive step (Article 33(3) PCT)

The subject-matter of claims 1, 3, 5-10 and 12-15 which lacks novelty does not offer a basis for acknowledging an inventive step.

The novel subject-matter of claims 1, 3, 5-10 and 12-15, and the subject-matter of claims 2 and 4, does not involve an inventive step:

# WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY (SEPARATE SHEET)

International application No.

PCT/IB2005/000597

D1, which is considered to represent the closest prior art, describes N-(4-pyrazolyl) amides useful as insecticides or nematocides, see in particular claims 1 and 10.

In the light of the disclosure of D1 the problem underlying the present application can be seen in the provision of further pesticides.

To solve this problem, the present application proposes to replace the amide group of the compounds of D1 by a sulphonamide group.

Such a structural modification is however an obvious measure in the design of further pesticidal compounds, particularly in view of the teachings of D2 (see the definition of  $R_3$ ) and of D3 (see example 8), which does not involve an inventive step in the absence of substantiated, directly resulting, unexpected effects.

#### Industrial applicability (Article 33(4) PCT)

The compounds, compositions and methods of claims 1-14 can be applied in the chemical industry.

For the assessment of the present claim on the question whether it is industrially applicable, no unified criteria exist in the PCT Contracting States.

# This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

### BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:		
BLACK BORDERS		
☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES		
☐ FADED TEXT OR DRAWING		
☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING		
☐ SKEWED/SLANTED IMAGES		
☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS		
☐ GRAY SCALE DOCUMENTS		
LINES OR MARKS ON ORIGINAL DOCUMENT		
REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY		
VI OTHER.		

### IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.